Reminiscences of my contributions to Thrombosis and Haemostasis: Urine tissue factor and plasma plasmin inhibitor

 

 

MissingLinkText

• References

• 1 Grunke W. Studien über die Blutgerinnung mit besonderer Berücksichtigung der Haemophilie. I. Mittei-lung: Einfluss des Harnes auf die Gerinnung haemophilen Blutes. ZGes Exp Med 1935; 96: 512-516.
• 2 Caldwell J, von Kaulla KN, von Kaulla E. et al. Procoagulant material from human urine in prothrombin activation. Thromb Diath Haemorrh 1963; 9: 53-61.
• 3 Aoki N, von Kaulla KN. Theprocoagulant in human urine: Purification, assay and some biochemical and physiological properties. Thromb Diath Haemorrh 1966; 16: 586-605.
• 4 Aoki N, von Kaulla KN. Partial purification and characterization of urinary procoagulant. Thromb Diath Haemorrh 1971; 26: 235-250.
• 5 Matsuda M, Aoki N. Purification and characterization of procoagulant in human urine. Thromb Res 1978; 13: 311-324.
• 6 Kurosawa S, Matsuda M, Aoki N. Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X. Thromb Res 1984; 33: 595-606.
• 7 Pitlick FA. Concanavalin A inhibits tissue factor coagulant activity. J Clin Invest 1975; 55: 175-179.
• 8 Carty N, Taylor I, Roath OS. et al. Urinary tissue factor activity in malignancy. Thromb Res 1990; 57: 473-478.
• 9 Qi H, Koyama T, Nishida K. et al. Urinary procoagulant activity and tissue factor levels in patients with diabetes mellitus. Haemostasis 1997; 27: 57-64.
• 10 Koyama T, Nishida K, Ohdama S. et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-347.
• 11 Wiggins RC, Glatfeltor A, Kshirsagar B. et al. Procoagulant activity in normal human urine associated with subcellular particles. Kidney Int 1986; 29: 591-597.
• 12 Matsuda M, Aoki N, Kawaoi A. Localization of urinary procoagulant in the human kidney. Kidney Int 1979; 15: 612-617.
• 13 Lwaleed BA, Bass PS, Francis JL. et al. Functional and structural properties of urinary tissue factor. Nephrol Dial Transplant 1999; 14: 588-596.
• 14 Matsumura T, Hutt MP, von Kaulla KN. Urinary pro-coagulant excretion in experimental renal disease. Pro Soci Exptl Biol Med 1968; 127: 147-153.
• 15 Matsumura T, Hutt MP, von Kaulla KN. Urinary pro-coagulant excretion and its relation to kidney function. Nephron 1970; 7: 165-177.
• 16 Sugawara T, Yamabe H, Osawa H. et al. Tissue factor pathway inhibitor production by human proximal tubular epithelial cells in culture. Thromb Res 2003; 110: 141-147.
• 17 Nestoridi E, Kushak RI, Duguerre D. et al. Upregulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 2005; 67: 2254-2266.
• 18 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissue: Implication for disorders of hemostas is and thrombosis. Am J Pathol 1989; 134: 1087-1097.
• 19 Fleck RA, Rao LVM, Rapaport SI. et al. Localization of human tissue factor antigen by immuno-stain-ingwith mono-specific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59: 421-437.
• 20 Bukovsky A, Labarrere CA, Haag B. et al. Tissue factor in normal and transplanted human kidney. Transplantation 1992; 54: 644-650.
• 21 Adamson AS, Francis JL, Roath OS. et al. Urinary tissue factor levels in transitional cell carcinoma of the bladder. J Urol 1992; 148: 449-452.
• 22 Adamson AS, Francis JL, Witherow RON. et al. Urinary tissue factor levels in prostatic carcinoma: A potential marker of metastatic spread. Br J Urol 1993; 71: 587-592.
• 23 Lwaleed BA, Vayro S, Racusen LC. et al. Tissue factor expression by a human kidney proximaltubular cell line in vitro: A model relevant to urinary tissue factor secretion in disease?. J Clin Pathol. 2006 doi:10.1136/jcp. 2006.039636.
• 24 Carty N, Taylor I, Roath OS. et al. Urinary tissue factor activity in colorectal disease. Br J Surg 1990; 77: 1091-1094.
• 25 Lwaleed BA, Chisholm M, Francis JL. Urinary tissue factor levels in patients with breast and colorectal cancer. J Pathol 1999; 187: 291-294.
• 26 Lwaleed BA, Bass PS, Chisholm M. et al. Urinary tissue factor in glomerulonephritis: a potential marker of glomerular injury?. J Clin Pathol 1997; 50: 336-340.
• 27 Koyama T, Ohdama S, Aoki N. Plasma tissue factor reflects endothelial cell injury rather than upregulation of tissue factor expression. Thromb Haemost 1997; 78: 972.
• 28 Bogdanov VY, Balasubramanian V, Hathcockb J. et al. Alternatively spliced human tissue factor: acirculating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
• 29 Aoki N, von Kaulla KN. Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers. Thromb Diath Haemorrh 1969; 22: 251-262.
• 30 Moroi M, Aoki N. Isolationand characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-5965.
• 31 Aoki N, Moroi M, Matsuda M. et al. The behavior of α2-plasmin inhibitor in fibrinolytic states. J Clin Invest 1977; 60: 361-369.
• 32 Saito H, Goldsmith GH, Moroi M. et al. Inhibitory spectrum of α2-plasm ininhibitor. Proc Natl Acad Sci USA 1979; 76: 2013-2017.
• 33 Gallimore MJ. Serum inhibitors of fibrinolysis. Br J Haematol 1975; 31: 217-231.
• 34 Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216.
• 35 Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553.
• 36 Hedner U. Studies on an inhibitor of plasminogen activation in human serum. Thromb Diath Haemorrh 1973; 30: 414-424.
• 37 Blombäck M, Abildgaard U, van den Besselaar AMHP. et al. Nomenclature of quantities and unitsin thrombosis and haemostasis(recommendation1993). Thromb Haemost 1994; 71: 375-394.
• 38 Yoshinaga H, Hirosawa S, Chung DH. et al. A novel point mutation of the splicing donor site in theintron 2 of the plasmin inhibitor gene. Thromb Haemost 2000; 84: 307-311.
• 39 Yoshinaga H, Nakahara M, Koyama T. et al. A single thymine nucleotide deletion responsible for congenital deficiency of plasmini nhibitor. Thromb Haemost 2002; 88: 144-148.
• 40 Aoki N. Thepast, present and future of plasmin inhibitor. Thromb Res 2005; 116: 455-464.
• 41 Wiman B, Collen D. Purification and characterization of human antiplasmin, thefast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26.
• 42 Yamanaka T, Ido K, Kimura K. et al. Alpha2-plasmin inhibitor levels in liver diseases. Igaku No Ayumi 1977; 103: 74-77.
• 43 Aoki N, Yamanaka T. The α2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 99-105.
• 44 Moroi M, Aoki N. Inhibition of plasminogen binding to fibrin by α2-plasmin inhibitor. Thromb Res 1977; 10: 851-856.
• 45 Aoki N, Moroi M, Tachiya K. Effects of α2-plasmin inhibitor on fibrinclotlysis. Its comparison with α2-macroglobulin. Thromb Haemost 1978; 39: 22-31.
• 46 Sakata Y, Aoki N. Cross-linking of α2-plasmin inhibitort of ibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297.
• 47 Sakata Y, Aoki N. Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and hemostasis. J Clin Invest 1982; 69: 536-542.
• 48 Aoki N. Clotretraction increases clot resistance to fibrinolysis by condensing α2-plasmin inhibitor cross linked to fibrin. Thromb Haemost 1993; 70: 376.
• 49 Tamaki T, Aoki N. Cross-linking of α2-plasmin inhibitort of ibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-14772.
• 50 Kimura S, Aoki N. Cross-linking site in fibrinogen for α2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-15595.
• 51 Aoki N, Saito H, Kamiya T. et al. Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-884.
• 52 Aoki N, Sakata Y, Matsuda M. et al. Fibrinolytic states in a patient with congenital deficiency of α2-plasmin inhibitor. Blood 1980; 55: 483-488.
• 53 Aoki N, Sakata Y, Ichinose A. Fibrin-associated plasminogen activation in α2-plasmin inhibitor deficiency. Blood 1983; 62: 1118-1122.
• 54 Miura O, Sugahara Y, Aoki N. Hereditary α2-plasmin inhibitor deficiency caused by a transport-deficient mutation(α2PI-Okinawa). J Biol Chem 1989; 264: 18213-18219.
• 55 Miura O, Hirosawa S, Kato A. et al. Molecular basis for congenital deficiency of α2-plasmin inhibitor. J Clin Invest 1989; 83: 1598-1604.
• 56 Miura O, Aoki N. Impaired secretion of mutant α2-plasmin inhibitor(α2PI-Nara) from COS-7and HepG2cells: molecular and cellular basis for hereditary deficiency of α2-plasmin inhibitor. Blood 1990; 75: 1092-1096.
• 57 Sugahara Y, Miura O, Yuen P. et al. Protein C deficiency caused by two mutant alleles, a5-nucleotide deletion and amissence mutation. Blood 1992; 80: 126-133.
• 58 Miura O, Sugahara Y, Aoki N. Intracellular transport-deficient mutants causing hereditary deficiencies of factors involved in coagulation and fibrinolysis. Thromb Haemost 1993; 69: 296-297.
• 59 Aoki N. Discovery of α2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost 2005; 3: 623-631.
• 60 Gallimore MJ. More on: discovery of α2-plasmin inhibitorand its congenital deficiency. J Thromb Haemost 2006; 4: 284-285.
• 61 Sumi Y, Ichikawa Y, Nakamura Y. et al. Expression and characterization of pro α2-plasmin inhibitor. J Biochem 1989; 106: 703-707.
• 62 Bangert K, Johnsen AH, Christensen U. et al. Different N-terminal forms of α2-plasmin inhibitorin human plasma. Biochem J 1993; 291: 623-625.
• 63 Koyama T, Koike Y, Toyota S. et al. Different NH2-terminal form with 12 additional residues of α2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-422.
• 64 Lee KN, Jackson KW, Christiansen VJ. et al. A novel plasma proteinase potentiates α2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-3788.
• 65 Lee KN, Jackson KW, Christiansen VJ. et al. Anti-plasmin-cleaving enzyme is a soluble form of fibrob-last activation protein. Blood 2006; 107: 1397-1404.
• 66 Christiansen VJ, Jackson KW, Lee KN. et al. The effect of a single nucleotide polymorphism on human α2-antiplasminactivity. Blood online Feb 22,. 2007 doi:10.1182/blood-2007-01-065185.
• 67 Okajima K, Koga S, Kaji M. et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1990; 63: 48-53.
• 68 Aoki N, Matsuda T, Saito H. et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75: 540-547.
• 69 Ohdama S, Aoki N. Increase of plasma thrombomodulin in systemic vasculitis. Thromb Haemost 1997; 77: 609.
• 70 Ohdama S, Takano S, Miyake S. et al. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994; 101: 109-113.
• 71 Ohdama S, Matsubara O, Aoki N. Plasma thrombomodulin in Wegener’s granulomatosis as an indicator of vascular injuries. Chest 1994; 106: 666-671.